Ledipasvir (GS 5885)

Catalog No. A13155

Ledipasvir (GS 5885)是丙型肝炎病毒HCV NS5A蛋白的抑制剂。

Product Citations

Sayuri Nitta, .et al. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients, Scientific Reports, 2019, 9: 5722 PMID: 30952914
Miyayama Y, .et al. Comparative study on the replication of HCV1b genome between wild type and cell culture adaptive mutant in regard to sensitivities against anti-HCV drugs, Microbiol Immunol, 2019, Dec 19 PMID: 31854467
Sayuri Nitta, .et al. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents, Sci Rep, 2016, 6: 34652 PMID: 27703205

Technical details

Catalog Num	A13155
M. Wt	889
Formula	C49H54F2N8O6
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1256388-51-8
Synonyms	GS5885, GS-5885
SMILES	CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

Biological Activity

Ledipasvir (GS 5885)是丙型肝炎病毒HCV NS5A蛋白的抑制剂。

Targets

HCV

Solubility *

In vitro	DMSO	93 mg/mL (104.61 mM)
	Water	Insoluble
	Ethanol	93 mg/mL (104.61 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	11.25 mL	56.24 mL	112.49 mL
0.5 mM	2.25 mL	11.25 mL	22.5 mL
1 mM	1.12 mL	5.62 mL	11.25 mL
5 mM	0.22 mL	1.12 mL	2.25 mL

*The above data is based on the productmolecular weight 889. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.